Back to Journals » OncoTargets and Therapy » Volume 10
Original Research
Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
12,773 | Dovepress* | 12,315+ | 1,191 | 13,506 | |
PubMed Central* | 458 | 223 | 681 | ||
Totals | 12,773 | 1,414 | 14,187 | ||
*Since 27 June 2017 |
View citations on PubMed Central and Google Scholar